Catabasis Pharmaceuticals Inc., of Cambridge, Mass., said phase I data published in The Journal of Clinical Pharmacology showed that edasalonexent (CAT-1004), an oral inhibitor of NF-kB, was safe, well-tolerated and inhibited activated NF-kB in adult subjects with Duchenne muscular dystrophy (DMD).